UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 5, 2015

 

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

 

 

 

 

 

 

Delaware

 

001-34899

 

16-1590339

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1380 Willow Road

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

 

 


 

 

 

 

Item 2.02.Results of Operations and Financial Condition.

On August 5, 2015, Pacific Biosciences of California, Inc. announced its financial results for its second fiscal quarter ended June 30, 2015. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

 

 

 

ITEM 9.01.

 

FINANCIAL STATEMENTS AND EXHIBITS.

 

 

5

 

 

 

 

 

 

 

(d)

 

Exhibits.

 

 

 

99.1

 

Press Release dated August 5, 2015  titled “Pacific Biosciences of California, Inc. Announces Second Quarter 2015 Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02).

 

 

 

 


 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Susan

 

 

 

 

 

Pacific Biosciences of California, Inc.

 

 

By:

 

/s/ Susan K. Barnes        

 

 

Susan K. Barnes

Executive Vice President, Chief Financial Officer & Principal Accounting Officer

 

Date: August 5, 2015

 


 

EXHIBIT INDEX

 

 

 

 

Exhibit No.

 

Description

99.1

 

Press Release dated August 5, 2015 titled “Pacific Biosciences of California, Inc. Announces Second Quarter 2015 Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02).

 




Exhibit 99.1

Pacific Biosciences of California, Inc. Announces Second Quarter 2015 Financial Results

Menlo Park, Calif. – August 5, 2015 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported a 118% increase in revenue with $24.9 million for the second quarter ended June 30, 2015, compared to $11.4 million for the second quarter of 2014.

Second quarter 2015 revenue includes product and service revenue of $11.3 million and $13.6 million of contractual revenue, while second quarter 2014 revenue includes product and service revenue of $9.7 million and $1.7 million of contractual revenue. Second quarter 2015 contractual revenue includes $10 million of milestone revenue and also reflects a higher quarterly amortization of the upfront Roche payment.

Gross profit increased $11.4 million to $14.5 million for the quarter, resulting in a gross margin of 58.2%, compared to gross profit of $3.1 million and a gross margin of 27.4% for the second quarter of 2014. The growth in gross profit and margin was driven by the additional $11.9 million Roche revenue at 100% margin.

Operating expenses totaled $25.9 million for the quarter, compared to $21.4 million for the second quarter of 2014. Operating expenses for the second quarters of 2015 and 2014 included non-cash stock-based compensation of $3.0 million and $2.1 million, respectively.

The net loss for the quarter was $11.9 million, compared to $19.1 million for the second quarter of 2014.

Cash and investments at June 30, 2015 totaled $72.7 million, compared to $101.3 million at December 31, 2014. 

Quarterly Conference Call Information 

Management will host a quarterly conference call to discuss its second quarter 2015 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers the PacBio® RS II Sequencing System to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences’ technology provides the industry’s highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. The PacBio RS II System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products for Roche, future milestone achievement and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contact:

Trevin Rard

650.521.8450


 

ir@pacificbiosciences.com


 

 

Pacific Biosciences of California, Inc.

Unaudited Condensed Consolidated Statement of Operations 

(amounts in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three-month Periods Ended June 30,

 

Six-month Periods Ended June 30,

 

2015

 

2014

 

2015

 

2014

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Product revenue

$

8,825 

 

$

7,749 

 

$

20,133 

 

$

15,614 

Service and other revenue

 

2,518 

 

 

1,980 

 

 

5,259 

 

 

4,061 

Contractual revenue

 

13,596 

 

 

1,696 

 

 

17,192 

 

 

3,392 

Total revenue

 

24,939 

 

 

11,425 

 

 

42,584 

 

 

23,067 

Cost of Revenue:

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

8,438 

 

 

6,271 

 

 

18,170 

 

 

13,440 

Cost of service and other revenue

 

1,995 

 

 

2,028 

 

 

3,981 

 

 

3,825 

Total cost of revenue

 

10,433 

 

 

8,299 

 

 

22,151 

 

 

17,265 

Gross profit

 

14,506 

 

 

3,126 

 

 

20,433 

 

 

5,802 

Operating Expense:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

15,043 

 

 

12,435 

 

 

29,526 

 

 

24,206 

Sales, general and administrative

 

10,821 

 

 

8,993 

 

 

21,593 

 

 

18,143 

Total operating expense

 

25,864 

 

 

21,428 

 

 

51,119 

 

 

42,349 

Operating loss

 

(11,358)

 

 

(18,302)

 

 

(30,686)

 

 

(36,547)

Interest expense

 

(715)

 

 

(701)

 

 

(1,412)

 

 

(1,387)

Other income (expense), net

 

138 

 

 

(133)

 

 

(10)

 

 

(88)

Net loss

$

(11,935)

 

$

(19,136)

 

$

(32,108)

 

$

(38,022)

Basic and diluted net loss per share

$

(0.16)

 

$

(0.27)

 

$

(0.43)

 

$

(0.55)

Shares used in computing basic and diluted net loss per share

 

74,733 

 

 

70,515 

 

 

74,442 

 

 

69,195 

 


 

 

Pacific Biosciences of California, Inc.

Unaudited Condensed Consolidated Balance Sheets

(amounts in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30,

 

December 31,

 

2015

 

2014

Assets

 

 

 

Cash and investments

$

72,674 

 

$

101,348 

Accounts receivable

 

3,950 

 

 

3,406 

Inventory

 

11,978 

 

 

11,335 

Prepaid and other current assets

 

1,587 

 

 

1,671 

Property and equipment

 

6,428 

 

 

6,601 

Other long-term Assets

 

153 

 

 

162 

Total Assets

$

96,770 

 

$

124,523 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

Accounts payable

$

5,818 

 

$

5,608 

Accrued expenses

 

11,316 

 

 

11,441 

Deferred service revenue

 

7,823 

 

 

7,250 

Deferred contractual revenue

 

19,328 

 

 

26,520 

Other liabilities

 

3,183 

 

 

3,687 

Financing derivative

 

899 

 

 

944 

Notes payable

 

14,567 

 

 

14,124 

Stockholders' equity

 

33,836 

 

 

54,949 

Total Liabilities and Stockholders' Equity

$

96,770 

 

$

124,523 

 

 

 

 

 

 

 


Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Pacific Biosciences of C... Charts.
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Pacific Biosciences of C... Charts.